title: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?
authors.forename: A L
authors.initials: AL
authors.lastname: Taylor
authors.forename: L L
authors.initials: LL
authors.lastname: Adams-Campbell
authors.forename: J T
authors.initials: JT
authors.lastname: Wright
mesh_terms: D001741:Black or African American / Q000706:statistics & numerical data; D016588:Anticarcinogenic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000208:ethnology / Q000517:prevention & control*; D016889:Endometrial Neoplasms / Q000139:chemically induced; D020847:Estrogen Receptor Modulators / Q000009:adverse effects*; D005260:Female; D006801:Humans; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects*; D020521:Stroke / Q000139:chemically induced; D013629:Tamoxifen / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000139:chemically induced; D044465:White People / Q000706:statistics & numerical data
chemical_list: D016588:Anticarcinogenic Agents; D020847:Estrogen Receptor Modulators; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen